Clinical Impact of Circulating MiR-18a in Plasma of Patients with Oesophageal Squamous Cell Carcinoma
Overview
Authors
Affiliations
Background: Several recent studies demonstrated that microRNAs are stably detectable in plasma/serum. We tested whether miR-18a, which is located in the miR-17-92 cluster and reported to be highly expressed in tissues of oesophageal squamous cell carcinoma (ESCC), served as a plasma biomarker in patients with ESCC.
Methods: This study was divided into three steps: (1) confirmation of higher miR-18a levels in primary ESCC tissues and cell lines than normal ESCC tissues and a human fibroblast cell line. (2) Evaluation of the plasma miR-18a assay using quantitative RT-PCR by comparing results from 106 consecutive patients with ESCC and 54 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in patients with ESCC.
Results: (1) Expression of miR-18a was significantly higher in ESCC tissues (P=0.0020) and ESCC cell lines (P=0.0121) than normal tissues and fibroblasts. (2) Plasma concentrations of miR-18a were significantly higher in ESCC patients than healthy volunteers (P<0.0001; ESCC patients vs healthy volunteers (mean±s.d.): 11.77±13.45 vs 0.73±0.54 amol μl(-1)). The value of the area under the receiver-operating characteristic (ROC) curve (AUC) was 0.9449. Furthermore, the ROC curves to detect early ESCC such as pTis-1 and pStage0-I showed AUCs of 0.9479 and 0.9642, respectively. (3) Plasma levels of miR-18a were significantly lower in postoperative samples than preoperative samples (P=0.0076).
Conclusion: Plasma miR-18a may be a very useful biomarker for cancer detection and the monitoring of tumour dynamics in patients with ESCC.
Imamura T, Komatsu S, Nishibeppu K, Kiuchi J, Ohashi T, Konishi H BMC Cancer. 2024; 24(1):907.
PMID: 39069624 PMC: 11283702. DOI: 10.1186/s12885-024-12676-x.
Kamiya H, Komatsu S, Takashima Y, Ishida R, Arakawa H, Nishibeppu K Br J Cancer. 2023; 130(4):671-681.
PMID: 38148376 PMC: 10876550. DOI: 10.1038/s41416-023-02532-3.
Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.
Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V Int J Mol Sci. 2022; 23(15).
PMID: 35897831 PMC: 9367895. DOI: 10.3390/ijms23158257.
MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients.
Kahng D, Kim G, Park S, Kim S, Lee M, Lee B J Korean Med Sci. 2022; 37(24):e197.
PMID: 35726148 PMC: 9247724. DOI: 10.3346/jkms.2022.37.e197.
Komatsu S, Imamura T, Kiuchi J, Takashima Y, Kamiya H, Ohashi T Am J Cancer Res. 2022; 11(12):6133-6146.
PMID: 35018247 PMC: 8727801.